Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial.
Xing Zhang, Bushu Xu, Qiuzhong Pan et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, phase I trial evaluated multiantigen stimulated cell therapy I (MASCT-I), alone or with ifosfamide, as first-line maintenance therapy in 31 patients with advanced sarcoma whose disease was controlled after chemotherapy. Treatment was well tolerated, with no treatment-related deaths. At a median follow-up of 63.6 months, median progression-free survival from maintenance initiation was 9.5 months, and median overall survival was 33.8 months. Survival outcomes were numerically better with ifosfamide combination therapy, while stronger antigen-specific immune responses were associated with longer survival.
Key findings
- Among 31 patients, median progression-free survival from maintenance initiation was 9.5 months.
- Median overall survival was 33.8 months after a median follow-up of 63.6 months.
- No treatment-related deaths occurred, and treatment was reported as well tolerated.
- Six of seven patients progression-free for over 4 years showed robust immune activation.
Why it matters
Advanced sarcoma has few established maintenance options after first-line chemotherapy. These long-term phase I findings provide preliminary evidence that MASCT-I can be delivered as maintenance and that antigen-specific immune activation may track with prolonged survival. The results are hypothesis-generating and may inform further evaluation of cellular immunotherapy in this setting.
What to keep in mind
The phase I trial included only 31 patients and had no stated control group, limiting conclusions about comparative efficacy.